Trials / Conditions / Bacterial Conjunctivitis

Bacterial Conjunctivitis

26 registered clinical trials studyying Bacterial Conjunctivitis — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis NCT06911424	Baxis Pharmaceuticals, Inc.	Phase 3
Completed	Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Sub NCT06363292	Laboratorios Sophia S.A de C.V.	Phase 1
Unknown	Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers NCT03235141	Beijing Tongren Hospital	Phase 1
Completed	Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo NCT03004924	Shire	Phase 3
Completed	Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctiv NCT02432807	Kurobe LLC	Phase 3
Completed	Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazu NCT02980523	Laboratorios Sophia S.A de C.V.	Phase 2
Completed	Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis NCT01877694	NovaBay Pharmaceuticals, Inc.	Phase 2
Terminated	Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conj NCT01740388	Bausch & Lomb Incorporated	Phase 3
Completed	An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin NCT01573910	Alcon Research	Phase 3
Terminated	Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunct NCT01330355	Bausch & Lomb Incorporated	Phase 3
Unknown	Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis NCT01227863	Azidus Brasil	Phase 3
Withdrawn	Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunct NCT01238783	Alcon Research	Phase 2
Completed	Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle NCT01175590	Bausch & Lomb Incorporated	Phase 3
Completed	Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis NCT00972777	Bausch & Lomb Incorporated	Phase 2 / Phase 3
Completed	Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis NCT00759148	Alcon Research	Phase 3
Completed	Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment NCT00798577	Alcon Research	Phase 4
Completed	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis NCT00518089	Allergan	Phase 3
Completed	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis NCT00509873	Allergan	Phase 3
Completed	A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis NCT00464438	Allergan	Phase 4
Completed	Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora NCT00312338	Alcon Research	Phase 4
Completed	AL-15469A for the Treatment of Bacterial Conjunctivitis NCT00332293	Alcon Research	Phase 3
Completed	AL-15469A for the Treatment of Bacterial Conjunctivitis NCT00331916	Alcon Research	Phase 3
Completed	Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis NCT00622908	Bausch & Lomb Incorporated	Phase 2
Completed	Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjun NCT00565123	Laser Microsurgery Centre, Poland	Phase 2 / Phase 3
Completed	Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunct NCT00105534	Merck Sharp & Dohme LLC	Phase 3
Completed	Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conju NCT00105469	Merck Sharp & Dohme LLC	Phase 3